ALXN Upgraded To Conviction Buy At Goldman

Symbols: ALXN
Tags: Goldman
Share

Analysts at Goldman Sachs upgrade Alexion Pharma (NASDAQ: ALXN) from "buy" to "conviction buy." The target price for ALXN has been raised from $57 to $62.

ALXN’s shares closed at $52.85 yesterday. More Analyst Ratings here


 
 
< Previous
Goldman Upgrades STJ To Sell
Next >
ONXX Upgraded To Buy At Goldman
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust

Special Offers:
Quick Cash Advance